Spots Global Cancer Trial Database for mbg453
Every month we try and update this database with for mbg453 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2) | NCT04266301 | Myelodysplastic... Leukemia, Myelo... | Sabatolimab Azacitidine Placebo | 18 Years - | Novartis | |
| A Study of MBG453 in Combination With Azacitidine and Venetoclax in AML Patients Unfit for Chemotherapy | NCT04150029 | Acute Myeloid L... | MBG453 Venetoclax Azacitidine | 18 Years - | Novartis | |
| Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2) | NCT04266301 | Myelodysplastic... Leukemia, Myelo... | Sabatolimab Azacitidine Placebo | 18 Years - | Novartis | |
| Phase Ib Study of Select Drug Combinations in Patients With Lower Risk MDS | NCT04810611 | Myelodysplastic... | MBG453 NIS793 canakinumab | 18 Years - | Novartis | |
| A Study of MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS). | NCT03946670 | Myelodysplastic... | MBG453 Placebo Hypomethylating... | 18 Years - | Novartis | |
| Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab. | NCT05201066 | Myelodysplastic... Leukemia, Myelo... | decitabine spartalizumab sabatolimab azacitidine venetoclax INQOVI (oral de... | 12 Years - 99 Years | Novartis | |
| STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDS | NCT04878432 | Myelodysplastic... | MBG453 Azacitidine Decitabine INQOVI (oral de... | 18 Years - 99 Years | Novartis | |
| Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab. | NCT05201066 | Myelodysplastic... Leukemia, Myelo... | decitabine spartalizumab sabatolimab azacitidine venetoclax INQOVI (oral de... | 12 Years - 99 Years | Novartis | |
| Trial of Anti-Tim-3 in Combination With Anti-PD-1 and SRS in Recurrent GBM | NCT03961971 | Glioblastoma Mu... | MBG453 | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Study of Select Combinations in Adults With Myelofibrosis | NCT04283526 | Primary Myelofi... Myelofibrosis PMF Post-Essential ... Post-Polycythem... | MBG453 NIS793 Spartalizumab Decitabine | 18 Years - | Novartis | |
| Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2) | NCT04266301 | Myelodysplastic... Leukemia, Myelo... | Sabatolimab Azacitidine Placebo | 18 Years - | Novartis | |
| A Study of MBG453 in Combination With Azacitidine and Venetoclax in AML Patients Unfit for Chemotherapy | NCT04150029 | Acute Myeloid L... | MBG453 Venetoclax Azacitidine | 18 Years - | Novartis |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
